Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6610 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-26 (rebusinessonline.com)
Biogen Unveils Plans for New Global Headquarters in Cambridge, Massachusetts -
CAMBRIDGE, MASS. — Biogen Inc. (NASDAQ: BIIB) has unveiled plans for its new global headquarters in Cambridge, located across the Charles River from Boston. The biotechnology company has selected Kendall Common, located at 75 Broadway, as the site of its new hub as part of a multi-year consolidation plan in Massachusetts that encompasses Biogen's existing facilities in the Kendall Square area of Boston. Specifically, Biogen has signed a 15-year lease to occupy 580,000 square feet of office and life sciences space at Kendall Common, which is being developed by a joint venture between Blackstone subsidiary BioMed Realty and the Massachusetts Institute of Technology (MIT) Investment Management Co. The space will feature upgraded workspaces and modern amenities, along with sustainable design elements such as advanced water conservation measures and energy-efficient systems. In addition, the building will house the Biogen CoLab, a classroom-style community laboratory and collaborative space.
Read more
2025-03-24 (investorshangout.com)
Biogen Sets Sights on Future with New Headquarters Plan - Investors Hangout
Discover Biogen's exciting plans for a new global headquarters at Kendall Common, shaping innovation and collaboration for the future.
Read more
2025-03-24 (bizjournals.com)
Biogen to move HQ to new tower in MIT Kendall developmentTipping plummets in Central Florida as restaurant workers face 46% dropTilman Fertitta plans to resign as Landry's CEO to take Trump roleThese Mass. colleges have the highest earning potentialSports and entertainment mogul buys mansion in Cherry Hills VillageCenter for Forensic Science Research lays off 30% of staff amid federal funding uncertaintyGenetic testing pioneer 23andMe 's saga takes a turn for the worse- San Francisco Business TimesSeattle
1 day ago
Read more
2025-03-24 (nasdaq.com)
Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 |
(RTTNews) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts.
Read more
2025-02-13 (endpts.com)
Biogen downplays capacity for M&A; Roche's SMA drug is approved as a tablet
Biotech news roundup: Odyssey layoffs, GSK relocates vaccine R&D, Aligos raises $105M, Terrain Bio launches, Gates Foundation backs antibiotics research, Neuphoria gets Merck milestone
Read more
2024-12-20 (bizjournals.com)
Biogen in talks to move to MIT's Volpe development, sources say
The move would carry major ramifications for Kendall Square and a sluggish life sciences real estate market.
Read more
2023-09-09 (fool.com)
Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?
Buying a biotech is a good move, but it might not be enough to entice investors.
Read more
2023-04-26 (bisnow.com)
BXP Focusing Investments On Labs, Apartments As Office Market Struggles
The REIT has made significant moves to diversify its portfolio amid office turmoil through major life sciences and residential projects in Boston and Virginia.
Read more
2023-04-17 (schaeffersresearch.com)
Bulls Blast Biotech Stock Before Earnings
Biogen (BIIB) is moving higher, after nabbing two pre-earnings bull notes
Read more
2022-11-27 (nbcdfw.com)
Stocks Close Lower, Dow Drops Nearly 500 Points as Supply Chain Concerns Mount Amid Protests in China
Stocks fell Monday as social unrest from China’s prolonged Covid restrictions weighed on markets.
Read more
2022-01-03 (biopharma-reporter.com)
Biogen and Eisai move forward with investigational Alzheimer's therapy
Lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer's disease, has been granted Fast Track designation by the US Food and Drug Administration (FDA).
Read more